Vanguard Group Inc. Sells 115,652 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Vanguard Group Inc. reduced its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,475,322 shares of the company’s stock after selling 115,652 shares during the period. Vanguard Group Inc. owned approximately 9.47% of Twist Bioscience worth $201,820,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Federated Hermes Inc. acquired a new position in Twist Bioscience during the 3rd quarter valued at $29,000. Trexquant Investment LP raised its position in shares of Twist Bioscience by 212.9% during the third quarter. Trexquant Investment LP now owns 64,363 shares of the company’s stock valued at $1,304,000 after buying an additional 43,794 shares during the last quarter. Gotham Asset Management LLC lifted its stake in shares of Twist Bioscience by 253.2% in the third quarter. Gotham Asset Management LLC now owns 42,598 shares of the company’s stock valued at $863,000 after buying an additional 30,537 shares during the period. Seven Eight Capital LP acquired a new stake in Twist Bioscience during the third quarter worth about $306,000. Finally, Graham Capital Management L.P. bought a new position in Twist Bioscience during the third quarter valued at about $304,000.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $47.32 on Wednesday. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $55.26. The firm has a market cap of $2.76 billion, a P/E ratio of -14.08 and a beta of 1.80. The business’s fifty day moving average is $44.55 and its two-hundred day moving average is $38.58.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. During the same quarter in the prior year, the firm earned ($1.06) EPS. The company’s revenue was up 25.1% on a year-over-year basis. On average, equities research analysts predict that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 4,163 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $154,572.19. Following the transaction, the chief executive officer now directly owns 509,986 shares in the company, valued at approximately $18,935,780.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Twist Bioscience news, CEO Emily M. Leproust sold 2,408 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $123,602.64. Following the transaction, the chief executive officer now directly owns 507,578 shares of the company’s stock, valued at $26,053,978.74. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 4,163 shares of Twist Bioscience stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $154,572.19. Following the sale, the chief executive officer now directly owns 509,986 shares of the company’s stock, valued at approximately $18,935,780.18. The disclosure for this sale can be found here. Insiders sold a total of 17,246 shares of company stock valued at $706,593 over the last quarter. Corporate insiders own 3.92% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on TWST shares. Evercore ISI raised their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Barclays lifted their target price on shares of Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, June 28th. Robert W. Baird increased their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Guggenheim began coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective on the stock. Finally, Scotiabank increased their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Twist Bioscience has an average rating of “Buy” and a consensus target price of $48.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.